According to the Center for Disease Control and Prevention in the US, tobacco accounts for the greatest number of preventable deaths worldwide by any single agent. Nicotine, the active ingredient of tobacco, activates receptors known as nAChRs and, remarkably, unlike most other drugs of abuse, it acts as a "pharmacological chaperone" to stabilise assembly of its receptors within the Endoplasmic Reticulum (ER) and increase their abundance at the cell surface (up-regulation).
Up-regulation of nAChRs plays a major role in nicotine addiction and, possibly, in the decreased susceptibility of smokers to Parkinson's disease.
Receptors containing an alpha6 subunit (alpha6 nAChRs) are abundant in several specific brain regions. Researchers from the California Institute of Technology in Pasadena used mice expressing alpha6 labelled with a fluorescent protein to show that exposure to nicotine - at a level comparable to that in human smokers up- regulated alpha6 nAChRs in these areas of the brain.
The researchers discovered that nicotine's ability to up-regulate alpha6 nAChRs relied on the retrograde transport of alpha6 nAChRs back from the Golgi to the ER by COPI-coated vesicles.
The authors believe that GolgiER cycling (involving COPI vesicles) may be a common mechanism for up-regulation of other nAChRs by nicotine.
Manipulation of this process could therefore help form new strategies for smoking cessation and neuroprotection against Parkinson's disease.
The study was published in The Journal of General Physiology.